Genfit S.A. (OTCMKTS:GNFTF – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 61,745 shares, an increase of 64.4% from the September 30th total of 37,557 shares. Based on an average daily volume of 91 shares, the short-interest ratio is presently 678.5 days.
Genfit Stock Performance
OTCMKTS GNFTF opened at $9.43 on Tuesday. The company has a fifty day moving average of $14.87 and a 200 day moving average of $11.66. Genfit has a 1 year low of $4.14 and a 1 year high of $16.50.
Genfit Company Profile
Genfit SA is a biopharmaceutical company headquartered in Lille, France, focused on developing treatments for serious diseases with significant unmet medical needs. The company’s research has historically centered on liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), and has expanded to rare and life-threatening conditions affecting the liver and other organs.
Genfit’s portfolio includes therapies and investigational programs targeting acute-on-chronic liver failure, cholestatic liver diseases, and lysosomal acid lipase deficiency.
See Also
- Five stocks we like better than Genfit
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
